Can ResMed Outrun Abbott Laboratories in the Next Rally?
Abbott Laboratories fell -10% during the past Day. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer ResMed gives you more. ResMed (RMD) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Abbott Laboratories (ABT) stock, suggesting you may be better off investing in RMD
- RMD’s quarterly revenue growth was 9.1%, vs. ABT’s 6.9%.
- In addition, its Last 12 Months revenue growth came in at 9.4%, ahead of ABT’s 6.4%.
- RMD leads on profitability over both periods – LTM margin of 33.5% and 3-year average of 30.3%.
These differences become even clearer when you look at the financials side by side. The table highlights how ABT’s fundamentals stack up against those of RMD on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| ABT | RMD | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 24.5 | 21.2 | RMD |
| Revenue Growth | |||
| Last Quarter | 6.9% | 9.1% | RMD |
| Last 12 Months | 6.4% | 9.4% | RMD |
| Last 3 Year Average | -0.6% | 13.3% | RMD |
| Operating Margins | |||
| Last 12 Months | 17.6% | 33.5% | RMD |
| Last 3 Year Average | 16.3% | 30.3% | RMD |
| Momentum | |||
| Last 3 Year Return | 2.1% | 11.9% | RMD |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: ABT Revenue Comparison | RMD Revenue Comparison
See more margin details: ABT Operating Income Comparison | RMD Operating Income Comparison
- Buy or Sell Abbott Laboratories Stock?
- Is Abbott Laboratories Stock Built to Withstand More Downside?
- How Did Abbott Fare In Q4 And What Lies Ahead?
- Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
- Why RMD Could Outperform Abbott Laboratories Stock
- Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
See detailed fundamentals on Buy or Sell RMD Stock and Buy or Sell ABT Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| ABT Return | 31% | -21% | 2% | 5% | 13% | -3% | 21% | ||
| RMD Return | 23% | -19% | -17% | 34% | 6% | 8% | 27% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% | <=== | |
| Monthly Win Rates [3] | |||||||||
| ABT Win Rate | 58% | 42% | 50% | 58% | 58% | 0% | 44% | ||
| RMD Win Rate | 50% | 50% | 58% | 50% | 58% | 100% | 61% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | 71% | <=== | |
| Max Drawdowns [4] | |||||||||
| ABT Max Drawdown | -3% | -31% | -16% | -8% | -1% | -3% | -10% | ||
| RMD Max Drawdown | -15% | -26% | -35% | -4% | -10% | 0% | -15% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | -7% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 1/22/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read RMD Dip Buyer Analyses to see how the stock has fallen and recovered in the past.
Still not sure about ABT or RMD? Consider portfolio approach.
Multi Asset Portfolios Offer More Upside With Less Risk
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices